[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wang Yusheng\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100571220","efficacy-and-safety-of-low-dose-conbercept-for-retinopathy-of-prematurity-therapy-100571220",false,"NCT06717412","Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy","Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy: A Multicenter, Prospective, Randomized, Double-blind, Non-inferiority Clinical Trial","Inclusion Criteria:\n\n* Preterm infants with less than or equal to 2000 grams of birth weight or less than or equal to 32 weeks of gestational age\n* Bilateral type 1 ROP with one of the following retinal findings in each eye\n* Zone I, stage 1+, 2+, 3+\u002F- disease, or\n* Zone II, stage 2+, 3+, disease, or\n* A-ROP\n\nExclusion Criteria:\n\n* Preterm infants with stage 4 or 5 ROP in one or both eyes\n* Have received any previous surgical or nonsurgical treatment for ROP, including laser photocoagulation, anti-VEGF therapy, vitrectomy\n* Have been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)\n* Have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer\n* Have active ocular infection within 5 days before or on the day of first investigational treatment\n* Have a history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes\n* Have any contraindication for intravitreal injection clearly stated in the instructions\n* Have any ocular structural abnormality that may affect efficacy assessments\n* Have a history of any other congenital or systemic conditions that are assessed by the investigator to have a significant risk of severe impact on visual function\n* Have any other medical conditions or clinically significant comorbidities or personal circumstances that are assessed by the investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments","ALL",{"count":18,"type":19},146,"ESTIMATED","INTERVENTIONAL",[22],"NA","Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)",[25],"Retinopathy of Prematurity (ROP)","RECRUITING","2025-04-01",{"date":29,"type":30},"2025-04-04","ACTUAL",{"date":32,"type":30},"2024-11-29",{"date":34,"type":19},"2026-12-31",{"name":36,"class":37},"Wang Yusheng","OTHER",3,""]